Dianthus Therapeutics, Inc. /DE/ (DNTH) Stock
5 of the hedge funds AlphaScala tracks reported DNTH in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $95.03M. Company insiders reported 0 open-market buys and 30 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own DNTH?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 975K | $95.03M | -39% |
| Marshall Wace | 129K | $12.55M | -62% |
| Millennium Management Israel Englander | 92K | $8.95M | -65% |
| D.E. Shaw David Shaw | 43K | $4.18M | -71% |
| Blackstone | 7K | $701.2K | -79% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Dianthus Therapeutics, Inc. /DE/ insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 17, 26 | Carr Edward | CHIEF ACCOUNTING OFFICER | SELL | 7.9K | $796K |
| Sep 17, 26 | Carr Edward | CHIEF ACCOUNTING OFFICER | SELL | 6.8K | $686K |
| Sep 17, 26 | Carr Edward | CHIEF ACCOUNTING OFFICER | SELL | 3.5K | $358K |
| Sep 17, 26 | Carr Edward | CHIEF ACCOUNTING OFFICER | SELL | 1.1K | $114K |
| Sep 17, 26 | Carr Edward | CHIEF ACCOUNTING OFFICER | SELL | 700 | $73K |
| Sep 1, 26 | Randhawa Simrat | EVP, Head of R&D | SELL | 2.6K | $273K |
| Sep 1, 26 | Randhawa Simrat | EVP, Head of R&D | SELL | 7.2K | $767K |
| Sep 1, 26 | Randhawa Simrat | EVP, Head of R&D | SELL | 13.3K | $1.4M |
| Aug 19, 26 | Read Simon | Director | SELL | 2.8K | $327K |
| Aug 10, 26 | Read Simon | Director | SELL | 70 | $7K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →DNTH price chart
Powered by TradingViewWhat does Dianthus Therapeutics, Inc. /DE/ do?
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases. It designs and delivers novel monoclonal antibodies and biologics with enhanced selectivity, potency, and dosing convenience compared to existing therapies, targeting validated immune pathways such as the classical complement pathway, plasmacytoid dendritic cells, and B cells. The company's lead candidate, DNTH103 (claseprubart), is a subcutaneous active C1s inhibitor in clinical trials for neuromuscular indications including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. DNTH212, a bifunctional fusion protein, addresses both innate and adaptive immune responses by reducing type 1 interferon production and suppressing B-cell function. Dianthus Therapeutics Inc. operates in the healthcare biotechnology sector, advancing investigational medicines aimed at transforming treatment options for immune-mediated conditions. Founded in 2019 and headquartered in New York, New York, with additional presence in Waltham, Massachusetts, the company is led by an experienced team of biotechnology and pharmaceutical executives.